GLP-1 medicines for type 1 diabetes Earlier this year, diaTribe convened a global panel of diabetes experts to write the first international consensus on the safe use of GLP-1 medications in type 1 diabetes, an area where people have been using these drugs off-label without much formal guidance
Van Genechten, W., Vuylsteke, K., Struijk, C., Swinnen, L
Clinical studies have shown that moderate weight loss, defined as a 5-10% reduction of body weight is associated with a clinically meaningful improvement of metabolic risk factors, including improved pancreatic -cell function, and an increased insulin sensitivity of adipose tissue, liver and skeletal muscle (Magkos et al, 2016
As weight decreases and energy improves (both from better thyroid management and GLP-1 therapy), gradually increase intensity
Often the real culprit is mild dehydration and electrolyte loss, which is fixable
Standard dosing follows a step-up schedule, increasing from 0.25 mg to 2.4 mg, as used in most trials